Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Symphogen logo — company profile

Symphogen

Founded 2000 Denmark Denmark 188 employees Debt Financing Total: $314.00M Biopharma, Biotechnology +1

General Information

Company Name Symphogen
Founded Year 2000
Location Denmark Denmark
Employees 188
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Debt Financing
Social

BounceWatch is an independent company data service, not affiliated with Symphogen. To contact Symphogen, visit symphogen.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Symphogen compare?

A PDF of Symphogen and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Symphogen soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Symphogen

Symphogen:

Symphogen A/S, a Servier company and the Centre of Excellence for Antibodies, operates within in research, early clinical stages and CMC biologics development from research to market. Supporting Servier’s commitment to improve patients health and the R&D strategy within oncology and immune-oncology - Symphogen’s strategic focus is to apply our streamlined and effective antibody platform and capabilities in the discovery and early development of highly differentiated antibodies. The aim is to develop novel compounds either as combination or as stand-alone therapies for difficult to treat cancers.

Founded in 2000 and headquartered in Denmark, Symphogen operates in the Biopharma, Biotechnology, Pharmaceutical industries. The company received a €67.50M Debt Financing investment on 22 October 2015 from Novo Holdings and PKA.

Business keywords: biologics development, antibodies, oncology, immune-oncology, R&D strategy, clinical stages, compounds, therapies, cancer treatment, drug development

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Debt Financing €67.50M 2
Novo Holdings PKA
Novo Holdings, PKA
22 Oct 2015
Private Equity Round €41.00M 3
Novo Holdings PKA
Novo Holdings, PKA +1
03 May 2013
Venture Round €100.00M 3
Novo Holdings PKA
Novo Holdings, PKA +1
06 Jan 2011
Venture Round €33.00M 1
Essex Woodlands Healthcare Partners
02 Feb 2009
Private Equity Round Undisclosed 1
GenenFUND
10 Jun 2008
Venture Round €5.00M 1
Gilde Healthcare
Gilde Healthcare
01 Feb 2007
Series D $25.00M 7
Novo Holdings Gilde Healthcare Takeda Pharma
Novo Holdings, Gilde Healthcare +5
10 Jan 2006
Series C $25.00M 4
Novo Holdings
Novo Holdings, SLS Venture +2
05 Nov 2004
Series B $2.50M -
01 Mar 2004
Series B $15.00M 4
Novo Holdings Danske Bank
Novo Holdings, Danske Bank +2
22 Jan 2002

Symphogen Alternatives & Competitors

View All Alternatives
Symphogen vs
Apollomics
Apollomics United States

We are a biopharmaceutical company committed to the discovery and development of mono- and combinati...

Post-IPO Equity
26 employees
Biotechnology, Health Care
Symphogen vs
Pyxis Oncology
Pyxis Oncology United States

Charting a course to therapeutics for difficult-to-treat cancer.

68 employees
Biotechnology, Health Care
Symphogen vs
Harbour BioMed
Harbour BioMed United States

#DrugDiscovery #AntibodyDiscovery #AI #Biologics #ADC #Bispecific #Oncology #Immunology #Neuroscienc...

IPO
114 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Symphogen

Symphogen A/S, a Servier company and the Centre of Excellence for Antibodies, operates within in research, early clinical stages and CMC biologics development from research to market. Supporting Servier’s commitment to improve patients health and the R&D strategy within oncology and immune-oncology...
Symphogen was founded in 2000.
Symphogen is headquartered in Denmark.
Symphogen operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on biologics development, antibodies, oncology and immune-oncology.
Symphogen has approximately 188 employees.
Symphogen has completed 10 funding rounds, raising a total of $314.00M. The latest funding stage is Debt Financing.
Top alternatives and competitors to Symphogen include Apollomics, Pyxis Oncology, Harbour BioMed, Compass Therapeutics Inc., Biotecnol Limited. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Symphogen and Apollomics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Symphogen, https://bouncewatch.com/company/symphogen, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout